Table 5 Univariate and multivariable analyses of brain PFS and OS in patients with brain metastasis at baseline (N = 53)

Prior capecitabine vs. no prior capecitabine

1.20

0.68-2.11

0.5377

1.22

0.67-2.22

0.5195

Hormone receptor positive vs. hormone receptor negative

0.56

0.31 -1.00

0.0507

0.62

0.34-1.13

0.1190

0.38

0.20-0.72

0.0031

Best systemic response SD < 6 m, PD vs. CR, PR, SD ≥ 6 m

2.47

1.39-4.40

0.0022

3.55

1.89-6.67

<0.0001

Median trastuzumab duration, wks ≥35.4 vs. <35.4

0.85

0.48-1.50

0.5672

0.45

0.24-0.85

0.0140

0.50

0.25-0.99

0.0476

Age at ≥50 vs. <50

0.67

0.36-1.23

0.1925

1.13

0.61-2.13

0.6958

No. of metastasis ≥3 vs. <3

0.81

0.44-1.48

0.4918

1.10

0.57-2.13

0.7733

No. of prior chemotherapy regimens >3 vs. ≤ 3

0.88

0.48-1.61

0.6835

1.48

0.79-2.76

0.2169

Pattern of metastasis Visceral only vs other

1.51

0.80-2.85

0.1994

1.16

0.58-2.31

0.6778

Median TTbrainP, wks ≥30.7 vs. <30.7

0.44

0.24-0.82

0.0095

0.58

0.29-1.16

0.1223

Median interval from brain metastasis diagnosis to study enrollment, wks ≥8.1 vs. <8.1

1.42

0.80-2.53

0.2365

1.49

0.81-2.74

0.2032

Brain response* SD < 6 m, PD vs. CR, PR, any response, SD ≥ 6 m

7.44

3.42-16.18

<0.0001

1.79

0.85-3.77

0.1263

Brain response & systemic response Else vs . Both of CR, PR, SD ≥ 6 m

2.82

1.57-5.09

0.0006

3.16

1.68-5.96

0.0004

3.65

1.95-6.85

<0.0001

2.18

1.07-4.42

0.0311